Your browser is no longer supported. Please, upgrade your browser.
CTXR Citius Pharmaceuticals, Inc. daily Stock Chart
Citius Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.76 Insider Own39.70% Shs Outstand8.71M Perf Week-22.94%
Market Cap12.01M Forward P/E- EPS next Y-0.54 Insider Trans- Shs Float4.96M Perf Month-55.36%
Income-13.10M PEG- EPS next Q-0.32 Inst Own6.60% Short Float3.10% Perf Quarter-45.75%
Sales- P/S- EPS this Y17.30% Inst Trans- Short Ratio1.10 Perf Half Y-61.25%
Book/sh2.35 P/B0.59 EPS next Y62.20% ROA-52.30% Target Price10.50 Perf Year-52.60%
Cash/sh0.57 P/C2.40 EPS next 5Y- ROE-63.40% 52W Range1.12 - 5.49 Perf YTD-63.70%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-74.87% Beta-
Dividend %- Quick Ratio2.00 Sales past 5Y- Gross Margin- 52W Low23.16% ATR0.41
Employees1 Current Ratio2.00 Sales Q/Q- Oper. Margin- RSI (14)32.95 Volatility45.01% 18.87%
OptionableNo Debt/Eq0.01 EPS Q/Q19.50% Profit Margin- Rel Volume0.64 Prev Close1.38
ShortableNo LT Debt/Eq0.00 Earnings- Payout- Avg Volume140.13K Price1.38
Recom2.00 SMA20-38.21% SMA50-43.25% SMA200-58.32% Volume0 Change0.00%
Aug-13-18 05:00PM  Citius Announces Closing of $10.0 Million Underwritten Offering Priced At-the-Market PR Newswire
Aug-09-18 01:55PM  Pot Stocks & Biotech Stocks to Watch in 2018 & Beyond ACCESSWIRE +48.25%
06:00AM  Citius Announces Pricing of $10.0 Million Underwritten Offering Priced At-the-Market PR Newswire
Jul-31-18 09:30AM  CTRXs Ph3 Mino-Lok Fills Unmet Need for Catheter-Related Blood Infection Antibiotic Zacks Small Cap Research -6.04%
Jul-24-18 08:00AM  Citius Announces The Notice Of Allowance From The USPTO On The Advanced Stability Patent Application For Mino-Lok® PR Newswire +8.09%
Jul-13-18 10:48AM  Citius Announces Key Addition to its Scientific Advisory Board PR Newswire +5.46%
Jul-09-18 08:00AM  Citius Provides Clinical Update And Progress Of The Mino-Lok® Phase 3 Trial PR Newswire
Jun-19-18 08:00AM  Citius Announces United States Patent & Trademark Office Registered the Company's Mino-Lok® Trademark PR Newswire
Mar-29-18 08:00AM  Citius Announces $2.0 Million Registered Direct Offering Priced At-the-Market PR Newswire
Mar-06-18 08:00AM  Citius Reports Progress in Hemorroid Treatment Program PR Newswire
Feb-15-18 08:00AM  Citius Announces Enrollment Of First Patient In The Mino-Lok Phase 3 Trial PR Newswire
Feb-13-18 08:00AM  Citius Publishes Expert Roundtable Discussion On Treatment Considerations For Catheter Related Bacteremias PR Newswire
Jan-31-18 08:00AM  Citius Pharmaceuticals to Present at BIO CEO & Investor Conference PR Newswire
Jan-04-18 08:00AM  Citius Pharmaceuticals to Present at Biotech Showcase 2018 PR Newswire
Dec-18-17 08:00AM  Citius Announces $6 Million Registered Direct Offering Priced At-the-Market PR Newswire -5.11%
Dec-06-17 08:00AM  Mino-Lok Phase 3 Clinical Trial Supplies Shipped to Sites PR Newswire
Dec-04-17 01:36PM  Citius Pharmaceuticals to Present at the 10th Annual LD Micro Invitational PR Newswire
Nov-14-17 08:00AM  Inserting And Removing Central Venous Catheters Cause Significant Discomfort In Cancer Patients And At Times Is Unnecessary PR Newswire
Nov-07-17 08:00AM  International Study at MD Anderson Sister Institutions Supports Mino Lok Phase 2b Results: Poster Presented at ID Week PR Newswire +8.16%
Oct-31-17 07:15PM  Is Citius Pharmaceuticals Incs (CTXR) Balance Sheet Strong Enough To Weather A Storm? Simply Wall St. +5.92%
08:00AM  Citius Pharmaceuticals, Inc. Receives "Fast Track" Designation By FDA For Mino-Lok Investigational Trial PR Newswire
Oct-17-17 09:00AM  Citius Pharmaceuticals to Present at the Dawson James 2017 Small Cap Growth Stock Conference PR Newswire
Oct-11-17 09:00AM  Citius Pharmaceuticals Issues Shareholder Letter PR Newswire +5.31%
Sep-26-17 03:47PM  Why Citius Pharmaceuticals Looks Undervalued
Sep-05-17 07:00AM  Citius Pharmaceuticals, Inc. Provides Phase 3 Update On Mino-Lok Clinical Trial Following FDA Meeting PR Newswire
Aug-10-17 11:30AM  Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) to Ring The Nasdaq Stock Market Opening Bell GlobeNewswire
Aug-08-17 11:25AM  Citius Pharmaceuticals, Inc. Announces Closing of Public Offering PR Newswire
Aug-03-17 09:31AM  Citius Pharmaceuticals, Inc. Prices $6,800,000 Public Offering And Listing On The Nasdaq Capital Market PR Newswire -30.18%
Jun-13-17 10:37AM  Citius Pharmaceuticals Presents At The 2017 Marcum MicroCap Conference PR Newswire -5.44%
Jun-08-17 05:00PM  Citius Pharmaceuticals Announces Reverse Stock Split PR Newswire +13.19%
Jun-06-17 12:30PM  Citius Pharmaceuticals to Present at the 7th Annual LD Micro Invitational PR Newswire
Mar-23-17 07:00AM  Citius Pharma Announces Addition of South America to World License PR Newswire +6.11%
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, and prescription products. The company develops Mino-Lok product, which has completed Phase IIb clinical trials for the treatment and salvage of infected central venous catheters in patients with catheter related bloodstream infections; and Hydro-Lido product, a topical formulation of hydrocortisone and lidocaine that is intended for the treatment of hemorrhoids. It has a collaboration and license agreement with Alpex Pharma S.A. to develop and commercialize orally disintegrating tablet formulations of pharmaceutical products in United States, Canada, and Mexico. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.